In particular, tyrosine kinase inhibitors (TKIs) and monoclonal antibodies against PD-1/PD-L1 axis are becoming the first-line therapeutic options for NSCLC patients positive to these targets. Here, CD274 is linked to non-small cell lung carcinoma.